Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment ParadigmAccesswire • Friday
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML StudiesAccesswire • Wednesday
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor TrialAccesswire • 11/11/24
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business UpdateAccesswire • 11/07/24
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq RulesAccesswire • 09/18/24
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq RulesAccesswire • 09/17/24
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 08/15/24
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business UpdateAccesswire • 08/08/24
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq RulesAccesswire • 06/28/24
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MAAccesswire • 05/14/24
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business UpdateAccesswire • 05/08/24
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe ConferenceAccesswire • 03/18/24
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business UpdateAccesswire • 03/05/24
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance PlanAccesswire • 03/04/24
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business UpdateAccesswire • 11/14/23
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business UpdateAccesswire • 08/10/23